30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Reimbursement / Regulatory

DiFusion Gains FDA Clearance for Xiphos ZFUZE Biomaterial -

DiFusion received FDA 510(k) clearance for the Xiphos-ZF spinal interbody device made from ZFUZE biomaterial. Product launch will occur in 4Q19, and will be followed by an ACL repair screw in early 2020. ZFUZE is designed to present an alternative to the limitations of PEEK and titanium for load-bearing implants. Studies have shown that ZFUZE material elicits a pro-reparative M2 macrophage response and significant reductions in Interleukin (IL) 1-Beta and IL6, which are cytokine markers for prolonged inflammation and associated with fibrous tissue formation.